Ganymede Bio, a Palo Alto, Calif.-based cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, has announced that it raised $12.75 million in Series A funding.

The round was led by Caffeinated Capital. This follows a $2.9 million seed round completed earlier this year, bringing the total to over $15.6 million. 

The new capital will support the ongoing development of the company’s cloud-native data platform, cloud IDE, and self-service tooling.

“Ganymede's speed and flexibility in integrating instruments through Lab-as-Code has been incredibly powerful for us,” said Angelo Stracquatanio, CEO and founder of Apprentice, one of Ganymede’s earliest partners. “We're proud to be partnering across biopharma manufacturing and R&D to get therapeutics to patients faster than ever."

Ganymede’s data platform is powered by its revolutionary Lab-as-Code core technology. It enables scientists and bioinformaticians to write their real-time integrations and scientific analysis in a low-code cloud IDE by directly connecting to any lab instrument or scientific software, ultimately bringing entire labs and manufacturing sites onto the cloud—and fast. Ganymede also offers end-to-end enterprise services and builds custom integrations for clients.

Company: Ganymede Bio, Inc. 

Raised: $12.75M

Round: Series A

Funding Month: December 2022

Lead Investors: Caffeinated Capital

Additional Investors:

Company Website: https://www.ganymede.bio/

Software Category: Biotech Software Engineering

About the Company: Ganymede is the first PaaS for biotech software engineering. Quickly integrate apps, import data, or design pipelines using a powerful bio-aware low-code platform. Ganymede is the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries. Its Lab-as-Code technology integrates physical lab instruments, apps, data pipelines, and third-party partners like CROs and CDMOs in a single cloud data layer. Ganymede accelerates time to innovation by giving scientists the ability to automate the world around them using cloud-controlled data flows. 

Source: https://www.businesswire.com/news/home/20221220005248/en/Ganymede-Bio-the-Cloud-Provider-Purpose-Built-for-the-Life-Sciences-and-Manufacturing-Industries-Raises-12.75-Million-in-Series-A-Funding